183 related articles for article (PubMed ID: 37726740)
21. BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment.
Busche S; John K; Wandrer F; Vondran FWR; Lehmann U; Wedemeyer H; Essmann F; Schulze-Osthoff K; Bantel H
Cell Death Dis; 2021 Jul; 12(8):736. PubMed ID: 34312366
[TBL] [Abstract][Full Text] [Related]
22. Alpha7 nicotinic acetylcholine receptor expression in Sorafenib-resistant Hepatocellular carcinoma cells.
Nour MA; Kheradmand F; Rasmi Y; Baradaran B
Med Oncol; 2022 Aug; 39(11):165. PubMed ID: 35972579
[TBL] [Abstract][Full Text] [Related]
23. Small interfering RNA targeting alpha7 nicotinic acetylcholine receptor sensitizes hepatocellular carcinoma cells to sorafenib.
Hajiasgharzadeh K; Somi MH; Mansoori B; Khaze Shahgoli V; Derakhshani A; Mokhtarzadeh A; Shanehbandi D; Baradaran B
Life Sci; 2020 Mar; 244():117332. PubMed ID: 31962133
[TBL] [Abstract][Full Text] [Related]
24. Diarylheptanoids/sorafenib as a potential anticancer combination against hepatocellular carcinoma: the p53/MMP9 axis of action.
Elmetwalli A; Diab T; Albalawi AN; El-Naggar SA; El-Far AH; Ghedan AR; Alamri ES; Salama AF
Naunyn Schmiedebergs Arch Pharmacol; 2023 Oct; 396(10):2501-2517. PubMed ID: 37145126
[TBL] [Abstract][Full Text] [Related]
25. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
Kim MN; Lee SM; Kim JS; Hwang SG
Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
[TBL] [Abstract][Full Text] [Related]
26. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
27. Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
Ishijima N; Kanki K; Shimizu H; Shiota G
Cancer Sci; 2015 May; 106(5):567-75. PubMed ID: 25683251
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in silico anticancer activity of amygdalin on the SK-BR-3 human breast cancer cell line.
Moradipoodeh B; Jamalan M; Zeinali M; Fereidoonnezhad M; Mohammadzadeh G
Mol Biol Rep; 2019 Dec; 46(6):6361-6370. PubMed ID: 31583572
[TBL] [Abstract][Full Text] [Related]
29. Regulation of SIRT1/AMPK axis is critically involved in gallotannin-induced senescence and impaired autophagy leading to cell death in hepatocellular carcinoma cells.
Kwon HY; Kim JH; Kim B; Srivastava SK; Kim SH
Arch Toxicol; 2018 Jan; 92(1):241-257. PubMed ID: 28676953
[TBL] [Abstract][Full Text] [Related]
30. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
Hu YT; Shu ZY; Jiang JH; Xie QF; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):547-554. PubMed ID: 33051131
[TBL] [Abstract][Full Text] [Related]
31. Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma.
Dai J; Huang Q; Niu K; Wang B; Li Y; Dai C; Chen Z; Tao K; Dai J
Cancer Med; 2018 Nov; 7(11):5691-5703. PubMed ID: 30311444
[TBL] [Abstract][Full Text] [Related]
32. Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells.
Wang ST; Ho HJ; Lin JT; Shieh JJ; Wu CY
Cell Death Dis; 2017 Feb; 8(2):e2626. PubMed ID: 28230855
[TBL] [Abstract][Full Text] [Related]
33. Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths.
Jomen W; Ohtake T; Akita T; Suto D; Yagi H; Osawa Y; Kohgo Y
Biomed Pharmacother; 2022 Sep; 153():113363. PubMed ID: 35834989
[TBL] [Abstract][Full Text] [Related]
34. The potential chemotherapeutic effect of β-ionone and/or sorafenib against hepatocellular carcinoma via its antioxidant effect, PPAR-γ, FOXO-1, Ki-67, Bax, and Bcl-2 signaling pathways.
Abd-Elbaset M; Mansour AM; Ahmed OM; Abo-Youssef AM
Naunyn Schmiedebergs Arch Pharmacol; 2020 Sep; 393(9):1611-1624. PubMed ID: 32270258
[TBL] [Abstract][Full Text] [Related]
35. Hemistepsin A Inhibits Cell Proliferation and Induces G0/G1-Phase Arrest, Cellular Senescence and Apoptosis Via the AMPK and p53/p21 Signals in Human Hepatocellular Carcinoma.
Baek SY; Hwang UW; Suk HY; Kim YW
Biomolecules; 2020 May; 10(5):. PubMed ID: 32375410
[TBL] [Abstract][Full Text] [Related]
36. Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
Zhai B; Jiang X; He C; Zhao D; Ma L; Xu L; Jiang H; Sun X
Tumour Biol; 2015 Apr; 36(4):2323-34. PubMed ID: 25416439
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli.
Fernando J; Sancho P; Fernández-Rodriguez CM; Lledó JL; Caja L; Campbell JS; Fausto N; Fabregat I
J Cell Physiol; 2012 Apr; 227(4):1319-25. PubMed ID: 21604268
[TBL] [Abstract][Full Text] [Related]
38. Adenine inhibits growth of hepatocellular carcinoma cells via AMPK-mediated S phase arrest and apoptotic cascade.
Su WW; Huang JY; Chen HM; Lin JT; Kao SH
Int J Med Sci; 2020; 17(5):678-684. PubMed ID: 32210718
[No Abstract] [Full Text] [Related]
39. Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids
Liu G; Kuang S; Cao R; Wang J; Peng Q; Sun C
FASEB J; 2019 Sep; 33(9):10089-10103. PubMed ID: 31199678
[TBL] [Abstract][Full Text] [Related]
40. Hispidulin induces ER stress-mediated apoptosis in human hepatocellular carcinoma cells in vitro and in vivo by activating AMPK signaling pathway.
Han M; Gao H; Xie J; Yuan YP; Yuan Q; Gao MQ; Liu KL; Chen XH; Han YT; Han ZW
Acta Pharmacol Sin; 2019 May; 40(5):666-676. PubMed ID: 30218072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
